Annual report highlights progress in cancer research

The American Association for Cancer Research has unveiled its 2026 Cancer Progress Report, underscoring significant strides in cancer research and treatment. Keith Flaherty, M.D., chair of the 2026 Steering Committee, along with his team, has identified advances in comprehending, identifying, and combating cancer, as well as resources to aid patients and survivors.

The report reveals that between July 2025 and June 2026, the U.S. Food and Drug Administration (FDA) authorized 11 novel anticancer treatments, including a molecularly targeted therapy for a rare, aggressive brain tumor with a specific genetic mutation; the inaugural immune checkpoint inhibitor for ovarian cancer; and the first approval of a proteolysis-targeting chimera for breast cancer patients.

Furthermore, during the same period, the FDA granted new indications for five existing anticancer therapies; a wearable, noninvasive device for pancreatic cancer treatment; and multiple artificial intelligence (AI) tools to enhance early cancer detection and diagnosis.

The report delves into several burgeoning research domains, such as weight-loss interventions like glucagon-like peptide-1 receptor agonists to curb obesity-related cancer risks; AI applications to expedite research, drug development, cancer screening, diagnosis, and patient outcome prediction; and preventive and therapeutic vaccines.

Flaherty emphasized the accelerating pace of cancer research, stating, "Progress against cancer is proceeding rapidly, with more breakthroughs on the horizon." He urged investment in medical research, interdisciplinary collaboration, and support for the next generation of cancer scientists to accelerate discoveries and translate them into precise, biology-driven approaches that could revolutionize the lives of cancer patients.